Log in

NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Forecast & News

$51.89
-0.58 (-1.11 %)
(As of 02/17/2020 06:00 AM ET)
Today's Range
$51.29
Now: $51.89
$52.88
50-Day Range
$51.54
MA: $57.20
$62.51
52-Week Range
$51.00
Now: $51.89
$106.80
Volume207,811 shs
Average Volume223,691 shs
Market Capitalization$1.03 billion
P/E Ratio32.03
Dividend YieldN/A
Beta0.85
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$205.20 million
Cash Flow$2.30 per share
Book Value$23.50 per share

Profitability

Net Income$46.38 million

Miscellaneous

Employees113
Market Cap$1.03 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.


Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings data on Thursday, February, 6th. The biotechnology company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.59 by $0.06. The biotechnology company had revenue of $52.57 million for the quarter, compared to analysts' expectations of $58.75 million. Enanta Pharmaceuticals had a return on equity of 7.39% and a net margin of 18.00%. The company's revenue for the quarter was down 24.8% compared to the same quarter last year. During the same period last year, the firm earned $1.25 earnings per share. View Enanta Pharmaceuticals' Earnings History.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Enanta Pharmaceuticals.

What price target have analysts set for ENTA?

4 brokerages have issued 12 month price objectives for Enanta Pharmaceuticals' shares. Their forecasts range from $57.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $101.33 in the next twelve months. This suggests a possible upside of 95.3% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

What is the consensus analysts' recommendation for Enanta Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Has Enanta Pharmaceuticals been receiving favorable news coverage?

Media coverage about ENTA stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Enanta Pharmaceuticals.

Who are some of Enanta Pharmaceuticals' key competitors?

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), Tandem Diabetes Care (TNDM), NVIDIA (NVDA), Wells Fargo & Co (WFC), Ford Motor (F), Alibaba Group (BABA) and Tesla (TSLA).

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 63)
  • Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)
  • Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53)

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Farallon Capital Management LLC (8.83%), State Street Corp (4.19%), Renaissance Technologies LLC (3.69%), Acadian Asset Management LLC (1.74%), Goldman Sachs Group Inc. (1.68%) and Bank of New York Mellon Corp (0.95%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

Which major investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, FMR LLC, Marshall Wace North America L.P., AQR Capital Management LLC, Rafferty Asset Management LLC, UBS Group AG, Thrivent Financial for Lutherans and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Paul J Mellett and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

Which major investors are buying Enanta Pharmaceuticals stock?

ENTA stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Fairmount Funds Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Prudential Financial Inc., California Public Employees Retirement System, AJO LP and Aviva PLC. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $51.89.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $1.03 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  269 (Vote Outperform)
Underperform Votes:  308 (Vote Underperform)
Total Votes:  577
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel